Cocrystal Pharma, Inc. 4
4 · Cocrystal Pharma, Inc. · Filed Mar 5, 2015
Insider Transaction Report
Form 4
WILCOX GARY
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2015-03-03+16,835,237→ 16,835,237 total - Exercise/Conversion
Series B Preferred Stock
2015-03-03−82,090→ 0 total→ Common Stock (16,835,237 underlying)
Footnotes (1)
- [F1]Each share of Series B Convertible Preferred Stock held by the reporting person was automatically convertible for no additional consideration into 205.08308640 shares of the issuer's common stock at such time as the issuer obtained sufficient authorized capital. The issuer filed a charter amendment increasing its authorized common stock with the Secretary of State of Delaware on March 3, 2015, which caused the automatic conversion of the Series B Convertible Preferred Stock into common stock. The Series B Convertible Preferred Stock had no expiration date.